



(51) International Patent Classification:

C07D 413/04 (2006.01) *A61P 19/00* (2006.01)
A61K 31/422 (2006.01) *A61P 35/00* (2006.01)
A61P 3/00 (2006.01) *A61P 37/00* (2006.01)
A61P 11/00 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:

PCT/US2011/048361

(22) International Filing Date:

19 August 2011 (19.08.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/375,406 20 August 2010 (20.08.2010) US

(71) Applicant (for all designated States except US): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MARTOS, Jose L.** [GB/GB]; 28 Newberry Side, Basildon Essex SS15 5XB (GB). **CARLING, William R.** [GB/GB]; 28 Yeomans Close, Bishop's Stortford Hertfordshire CM23 4EU (GB). **WOODWARD, David F.** [GB/US]; 22736 Islamare Lane, Lake Forest, California 92630 (US). **WANG, Jenny W.** [US/US]; 2 Giverny, Newport Coast, California 92657 (US). **KANGASMETSA, Jussi J.** [SE/GB]; . (GB).

(74) Agents: **WURST, John** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE



(57) Abstract: The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein R₁ is selected from the group consisting of CO₂R₇ and CON(R₇)SO₂R₇ wherein R₁, R₂, R₃, R₄, and R₇ are as defined in the specification. The compounds may be administered to treat DP₁, FP, EP₁, EP₃, TP and/or EP₄ receptor mediated diseases or conditions.